AUCTORES
Globalize your Research
Research Article
*Corresponding Author: Nasser Mikhail, MD, MSc, Chief Endocrinology Division, Olive View-UCLA Medical Center, Sylmar, CA, USA
Citation: Mikhail N. (2021) Tirzepatide: A Useful Addition for Treatment of Type 2 Diabetes and Obesity J. Gastroenterology Pancreatology and Hepatobilary Disorders. 5(5) DOI: 10.31579/2641-5194/044
Copyright: © 2021, Nasser Mikhail, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 08 August 2021 | Accepted: 25 August 2021 | Published: 10 September 2021
Keywords: tirzepatide; incretins ; semaglutide ; GLP-1; GIP; efficacy; safety; weight loss
Background: Tirzepatide is a dual receptor agonist of the 2 incretin hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) which is currently under development.
Objective: To clarify the potential role of tirzepatide for treatment of type 2 diabetes and obesity.
Methods: Pubmed search until August 5th, 2021. Search terms were GLP-1, GIP, incretins, tirzepatide, efficacy, safety. Clinical trials and pertinent reviews were included.
Results: In one phase 3 clinical trial, mean reduction of glycated hemoglobin (HbA1c) with tirzepatide (5-15 mg/week) was -1.87 to -2.07% versus + 0.04% with placebo after 40 weeks. In another phase 3 randomized trial, tirzepatide decreased HbA1c levels by -2.01% to -2.3% versus -1.86% with semaglutide (1.0 mg/week) (P<0.0001). In the previous 2 studies, tirzepatide use was associated with dose-related mean weight loss at 40 weeks of -7.0 kg o -9.5 kg vs -0.7 kg with placebo (P<0.0001) and -7.6 kg to -11.2 kg vs -5.7 kg with semaglutide ((P<0.001). Tirzepatide had generally favorable effects on lipid profile, particularly on lowering serum triglyceride levels: -19% to -24.8% mean reduction compared with -11.5% with semaglutide. Gastrointestinal (GI) adverse effects were the commonest reported symptoms associated with tirzepatide use and occurred more frequently than with placebo and semaglutide. Hypoglycemia was reported more coomonly with high-dose terzipatide (1.7%) compared with semaglutide (0.4%). Drug discontinuation rates due to adverse effects were 6-8.5 % with tirzepatide vs 4.1% with semaglutide.
Conclusions: Available data from 2 short-term randomized trials suggest that tirzepatide may be more effective than placebo and the GLP-1 agonist semaglutide in reducing HbA1c levels and body weight. Pattern of safety profile of tirzepatide is similar to that of GLP-1 agonists, but frequency of GI adverse effects and hypoglycemia is more common with tirzepatide.
Tirzepatide (LY3298176) is a dual GIP/GLP-1 receptor agonist [1]. Its 39 amino acid sequence is mainly based on that of native GIP which consists of 42 amino acids [1]. Tirzepatide is attached to a 20-carbon fatty diacid moiety which binds to albumin. Albumin binding prolongs its half-life to approximately 5 days allowing once a week subcutaneous administration [2]. Tirzepatide has similar GIP receptor binding affinity to native GIP. Yet, it has 5 times lower affinity to GLP-1 receptor compared to native GLP-1 [2]. Thus, this drug was described as an imbalanced dual agonist in favor of GIP receptor over GLP-1 receptor activity [3]. Tirzepatide is currently under investigation in a series of phase 3 clinical trials (called SURPASS-1 through 6) [4]. Primary end point in these trials is the change in HbA1c levels from baseline to the end of treatment with tirzepatide versus comparator. SURPASS-1 and 2 trials were recently published [5, 6]. These studies are summarized in table 1 and represent the focus of this review.
Being a dual agonist of receptors of GLP-1 and GIP, tirzepatide would be expected to exert actions similar to those occurring subsequent to activation of these 2 receptors. However, the mechanism of action of tirzepatide does not reflect several agonistic effects of GIP. For instance, while both GLP-1 and GIP stimulate insulin secretion in healthy individuals, efficacy of GIP as anti-hyperglycemic agent in patients with type 2 diabetes may be severely compromised [7, 8]. Paradoxically, in some studies, GIP may even worsen post prandial hyperglycemia [9]. The latter effect may be at least in part due the finding that GIP, contrary to GLP-1, acutely increased glucagon plasma levels [7, 10]. Moreover, when administered to patients with type 2 diabetes receiving long-term treatment with the GLP-1 receptor agonist liraglutide, GIP did not acutely decrease energy intake and appetite nor increased energy expenditure, but increased plasma glucose and glucagon levels [10]. In addition, data regarding effects of GIP on weight loss are conflicting. Thus, GIP may enhance deposition of fat in adipose tissues and was therefore considered the “obesity hormone” [1, 11]. Finally, while GLP-1 delays gastric emptying, GIP does not exert such effect [7, 12]. To explain this paradox, some authors hypothesize that chronic activation of receptors of both GLP-1 and GIP by tirzepatide could result in desensitization of GIP receptors, which ultimately results in creating GIP antagonism [1].
Nevertheless, available clinical data have shown that terzipatide may improve insulin sensitivity. This was shown by the decrease in insulin resistance by tirzepatide vs placebo in the homeostatic model assessment of insulin resistance (HOMA-IR) in SURPASS-1 trial [5]. This amelioration in insulin sensitivity is caused in small part by weight loss. Thus, in one study, weight reduction explained 13% and 21% of improvement HOMA-IR with tirzepatide doses of 10 and 15 mg, respectively [13]. On the other hand, Fonesca et al [14] have shown that reduction in insulin resistance by semaglutide is primarily mediated by weight loss in subjects with type 2 diabetes.
Tirzepatide versus placebo
SURPASS-1 trial is a double-blind randomized trial that included 478 overweight/obese patients (mean weight 85.9 kg) with type 2 diabetes inadequately controlled on diet and exercise alone (mean HbA1c 7.9%) (Table 1) [5]. Participants were randomly assigned to once weekly tirzepatide 5 mg, 10 mg, 15 mg or placebo [5]. After 40 weeks, mean HbA1c levels decreased from baseline by -1.87, -1.89, and 2.07 percentage points with tirzepatide 5 mg, 10 mg and 15 mg, respectively vs a slight increase of +0.04 percentage points with placebo (all P <0>
In SURPASS-2 trial, patients with type 2 diabetes on metformin (n=1,878, mean weight 93.7 kg, mean HbA1c 8.2%) were randomized to receive once weekly tirzepatide 5 mg, 10 mg, 15 mg or the GLP-1 receptor agonist semaglutide 1 mg once weekly in an open-label fashion (table 1) [6]. At 40 weeks, mean reductions from baseline in HbA1c levels with tirzepatide 5 mg, 10 mg, and 15 mg were -2.01, -2.24 and -2.30 percentage points, respectively, as compared with -1.86 percentage points with semaglutide [6]. In fact, all terzipatide doses were statistically superior to semaglutide. In all treatment groups, HbA1c levels reached a trough after 24 weeks followed by a plateau [6].
Tirzepatide exerts a potent dose-related effect on weight loss that was far superior to that caused by semaglutide (-11.2 kg vs -5.7 kg) (table 1) [5.6]. Weight loss was observed as early as 4 weeks [5, 6]. Contrary to their effects on HbA1c levels that plateaued after 24 weeks, weight reduction associated with tirzepatide and semaglutide use continued until the end of intervention at 40 weeks [5, 6]. Mechanisms of weight loss associated with terzipatide use are not fully understood. Surprisingly, in SURPASS-2, decreased appetite was reported by only 0.4% in patients receiving tirzepatide and none of patients receiving semaglutide [6]. In SURPASS 1, decreased appetite was reported by 4-8% randomized to semaglutide versus 1% with placebo [5]. One factor that may contribute to weight loss induced by tirzepatide is the relatively common occurrence of nausea and vomiting associated with its use (table 1). Comparison of the extent of weight loss between patients who reported GI adverse effects with tirzepatide versus those who did not may clarify this issue. Unfortunately, investigators in the SURPASS-1 and -2 trials did not report such important information [5, 6].
Overview of SURPASS-1 and 2 trials of terzipatide
The main effect of tirzepatide on lipid panel is reduction of serum triglycerides [5, 6, 15]. In a post-hoc analysis of a phase 2 clinical trial, Wilson et al [15] showed that tirzepatide decreased plasma levels of apolipoprotein C III (apo III), the main regulator of triglyceride metabolism. In addition, terzipatide treatment increased serum mass of lipoprotein lipase, the enzyme responsible for clearance of circulating triglycerides [15]. Moreover, the decrease in apo CIII levels by tirzepatide emerged as the best predictor of changes in plasma triglycerides, whereas weight loss was a weak predictor for reduction in serum triglycerides [15]. In SURPASS-2, tirzepatide treatment was associated with dose-related significant reduction in serum triglycerides at 40 weeks vs baseline ranging from -19.0% to -24.8% compared with -11.5% with semaglutide (statistical significance not reported) [6]. However, no significant differences were found between tirzepatide and semaglutide in total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels [6]. Regarding high-density lipoprotein cholesterol (HDL-C) levels, there was 6.8-7.9% increase in the terzipatide groups at 40 weeks versus 4.4% increase with semaglutide (statistical significance was not mentioned). In the post-hoc analysis by Wilson et al [15], tirzepatide decreased small atherogenic LDL particles more than the GLP-1 agonist dulaglutide. Taken together, the above data suggest that tirzepatide has favorable effects on lipid profile.
Overall, terzipatide was fairly tolerated. However, in phase 3 trials, the drug discontinuation rates due to adverse effects among patients randomized to tirzepatide (10-15 mg) were approximately double those recorded among subjects randomized to placebo (5-7% vs 3%) and semaglutide (8.5% vs 4.1%) (Table 1) [5, 6].
The most common adverse effects of tirzepatide are related to the GI system, namely nausea, diarrhea and vomiting (table 1). They are dose-related, generally described as mild to moderate, and mainly occur in the first few weeks-months after starting therapy [5, 6]. Starting tirzepatide in small doses of 2.5 mg/week followed by slow up-titration (increase by 2.5 mg every 4 weeks) may be associated with decreased frequency of nausea compared with more rapid titration (starting by 5 mg/week, then doubling the dose after 2 weeks, then 15 mg after 4 weeks) [5,6,16]. When compared with semaglutide 1.0 mg, GI adverse effects were slightly more common with the highest dose of terzipatide (15 mg) (table 1). Nausea and vomiting are attributed in part to delay in gastric emptying, which usually subsides after several weeks [17]. In fact, Urva et al [17] have shown that tirzepatide caused delay in gastric emptying that was similar in magnitude to the selective GLP-1 agonist dulaglutide. This finding suggests that delay in gastric emptying is mainly driven by the GLP-1 receptor component of terzipatide.
The incidence of clinically significant hypoglycemia (defined as blood glucose levels <54>
Despite the encouraging preliminary results reported with tirzepatide use, this drug has several limitations. First, data is limited to 2 phase 3 trials lasting only 40 weeks. Thus, it is not known whether reductions of hyperglycemia and weight are durable. Second, patients with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73 m2 were excluded from these trials [5, 6]. One study by Urva et al [18] has shown that renal impairment including need for hemodialysis has no clinically relevant effects on pharmacokinetics of tirzepatide. However, the latter investigation was a single-dose study that used tirzepatide in a small dose of 5 mg [18]. Third, patients with diabetic maculopathy and proliferative retinopathy and HbA1c levels > 10.5% were also excluded. Fourth, long-term safety of tirzepatide, including its effects on cardiovascular and renal events, are not known.
No doubt, introduction of tirzepatide represents a welcome addition of a new class for potential treatment of type 2 diabetes and obesity. Available data that extend to 40 weeks suggest that this dual GLP-1 and GIP receptor agonist is clearly superior to selective GLP-1 agonists in terms of anti-hyperglycemic efficacy, weight loss, and reduction in levels of serum triglycerides. In general, tirzepatide has an acceptable safety profile. However, its use is associated with high frequency of GI adverse effects. Due to its superior efficacy in weight reduction, tirzepatide is currently being investigated as treatment for obesity in a randomized, double-blind trial called SURMOUNT-1 [4]. This trial is planning to recruit 2,400 subjects who do not have diabetes. The Federal Drug Administration (FDA) has recently approved in June 2021 high dose semaglutide (2.4 mg/week) (Wegovy@) for treatment of obesity irrespective of presence of diabetes [19]. It would be interesting to compare tirzepatide and semaglutide (2.4 g/week) head to head as anti-obesity agents. As weight loss is effective in treating non-alcoholic steatohepatitis (NASH), a phase 2 double-blind study (SYNERGY-NASH) is underway to evaluate tirzepatide for treatment of NASH [4].
Further data are needed to evaluate long-efficacy and safety of tirzepatide in various groups of patients with type 2 diabetes. For example, in poorly controlled type 2 diabetes patients (HbA1c >10%), in patients with CKD and those receiving other concomitant diabetes therapy such as insulin or sodium-glucose co-transporters 2 (SGLT-2) inhibitors. The impact of tirzepatide on incidence of cardiovascular and renal events and mortality is certainly of crucial importance. This issue is currently under investigation in SURPASS-CVOT trial. The latter study is a large (n=12,500) double-blind trial comparing tirzepatide with dulaglutide 1.5 mg/week and is expected to terminate in October 2024 [4].
The author has no conflict of interest to declare.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
